Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 619 results
Found 619 results.

2012

Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Hubbard JJ, Greenwell-Wild T, Barrett L, et al. "Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a." J. Infect. Dis.. 2012;205(9):1443-7.
Cimbro R, Vassena L, Arthos J, et al. "IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa." Blood. 2012;120(13):2610-9.
Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT. "Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study." Clin. Infect. Dis.. 2012;55(5):631-8.
Robertson K, Jiang H, Kumwenda J, et al. "Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study." Clin. Infect. Dis.. 2012;55(6):868-76.
Nielsen-Saines K, Komarow L, Cu-Uvin S, et al. "Infant outcomes after maternal antiretroviral exposure in resource-limited settings." Pediatrics. 2012;129(6):e1525-32.
McComsey GA, Kitch D, Daar ES, et al. "Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir." AIDS. 2012;26(11):1371-85.
Manion M, Rodriguez B, Medvik K, et al. "Interferon-alpha administration enhances CD8+ T cell activation in HIV infection." PLoS ONE. 2012;7(1):e30306.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Hermes A, Squires K, Fredrick L, et al. "Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women." HIV Clin Trials. 2012;13(6):308-23.
Krishnan S, Schouten JT, Atkinson B, et al. "Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2012;61(3):381-9.
Dong BJ, Zheng Y, Hughes MD, et al. "Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women." AIDS. 2012;26(7):833-41.
Lockman S, Hughes M, Sawe F, et al. "Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial." PLoS Med.. 2012;9(6):e1001236.
Gandhi RT, Coombs RW, Chan ES, et al. "No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;59(3):229-35.
Genberg BL, Wilson IB, Bangsberg DR, et al. "Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America." AIDS. 2012;26(11):1415-23.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Safren SA, Hendriksen ES, Smeaton L, et al. "Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world." AIDS Behav. 2012;16(2):266-77.
Simoni JM, Huh D, Wilson IB, et al. "Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study." J. Acquir. Immune Defic. Syndr.. 2012;60(5):466-72.
Li JZ, Paredes R, Ribaudo HJ, et al. "Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure." AIDS. 2012;26(2):185-92.
Yang Y, Degruttola V. "Resampling-based methods in single and multiple testing for equality of covariance/correlation matrices." Int J Biostat. 2012;8(1):Article 13.
Dooley KE, Park J-G, Swindells S, et al. "Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267." J. Acquir. Immune Defic. Syndr.. 2012;59(5):455-62.
Hogan CM, Degruttola V, Sun X, et al. "The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals." J. Infect. Dis.. 2012;205(1):87-96.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.
Johnson DC, Chasela C, Maliwichi M, et al. "Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi." PLoS ONE. 2012;7(7):e41011.
Tsibris AMN, Hu Z, Paredes R, et al. "Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures." J. Virol.. 2012;86(12):6416-26.
Brehm JH, Scott Y, Koontz DL, et al. "Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase." PLoS ONE. 2012;7(2):e31558.

Pages